European Commission Approves CStone's Sugemalimab for Stage III Non-Small Cell Lung Cancer
The European Commission has approved CStone Pharmaceuticals' sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval is for patients whose disease has not progressed following platinum-based chemoradiotherapy. This marks an expansion of sugemalimab's use following its initial approval for first-line NSCLC treatment.
CStone Pharmaceuticals announced that the European Commission (EC) has approved a new indication for sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression on ≥1% of tumor cells, no sensitizing EGFR mutations, or ALK, ROS1 genomic aberrations, and whose disease has not progressed following platinum-based chemoradiotherapy. This approval follows the initial EC approval for sugemalimab in first-line NSCLC treatment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251125-11926992), on November 25, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
